N
AKYA

Nuveen’s Akoya BioSciences AKYA Stock Holding History

Nuveen’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-393,183
Closed -$15.9M – 3278
2025
Q1 		$15.9M Buy
393,183
+352,356
+863% +$771K ﹤0.01% 1269
2024
Q4 		$93.5K Hold
40,827
– – ﹤0.01% 3295
2024
Q3 		$111K Hold
40,827
– – ﹤0.01% 3300
2024
Q2 		$95.5K Hold
40,827
– – ﹤0.01% 3307
2024
Q1 		$191K Hold
40,827
– – ﹤0.01% 3196
2023
Q4 		$199K Buy
40,827
+11,453
+39% +$47.6K ﹤0.01% 3218
2023
Q3 		$137K Hold
29,374
– – ﹤0.01% 3092
2023
Q2 		$217K Hold
29,374
– – ﹤0.01% 3081
2023
Q1 		$240K Sell
29,374
-246
-0.8% -$2.57K ﹤0.01% 2956
2022
Q4 		$283K Hold
29,620
– – ﹤0.01% 2995
2022
Q3 		$348K Hold
29,620
– – ﹤0.01% 3027
2022
Q2 		$381K Buy
29,620
+9,994
+51% +$104K ﹤0.01% 3068
2022
Q1 		$230K Hold
19,626
– – ﹤0.01% 3166
2021
Q4 		$242K Hold
19,626
– – ﹤0.01% 3210
2021
Q3 		$412K Buy
19,626
+7,525
+62% +$126K ﹤0.01% 3203
2021
Q2 		$234K Buy
+12,101
New +$250K ﹤0.01% 3237

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCA
Peddock Capital Advisors Braintree, Massachusetts $501M AUM 29.8% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Nuveen's AKYA Position: Q2 2025 in Review

Nuveen sold out of Akoya BioSciences (AKYA) in Q2 2025, closing a stake of 393,183 shares — an estimated $15.9M sold.

Nuveen first reported a position in AKYA in Q2 2021 and held it in 16 quarters. The position peaked at $15.9M in Q1 2025. 58 funds tracked by Wall St. Rank hold AKYA as of Q2 2025.

  • Nuveen reported no remaining Akoya BioSciences position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 393,183 Akoya BioSciences shares in Q2 2025, an estimated $15.9M.
  • Nuveen first reported a position in Akoya BioSciences in Q2 2021 and held it in 16 quarters.
  • Nuveen's Akoya BioSciences position peaked at $15.9M in Q1 2025.
  • 58 funds tracked by Wall St. Rank held Akoya BioSciences as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.